Eli Lilly and Company (LLY)
2 healthcare safe bets to buy ahead of Trump's pharmaceutical tariffs
United States President Donald Trump has hinted that the pharmaceutical sector will likely be the next to be hit with tariffs. While announcing on March 28, Trump did not specify the date or rates involved, but the decision will likely trigger more market uncertainty.
CHMP Recommends Against Approval of Eli Lilly's Kisunla Alzheimer's Drug -- Update
A key European regulatory committee has recommended against approval of Eli Lilly's Kisunla, saying the benefits of the Alzheimer's disease drug don't outweigh its risks.
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
EU medicines regulator rejects Eli Lilly's Alzheimer's drug
The European Union's drugs regulator on Friday rejected Eli Lilly's Alzheimer's drug Kisunla, saying the risk of serious brain swelling did not outweigh the treatment's small impact on slowing cognitive decline.
Lilly adds Alzheimer's to online offerings
Eli Lilly on Thursday expanded its direct-to-consumer online platform LillyDirect to include telehealth providers to diagnose and care for patients with Alzheimer's disease, potentially boosting sales of its drug Kisunla.
Eli Lilly, Palo Alto Networks Traders Take Note: Direxion's New Leveraged ETFs Are Here
Active traders have new, highly powered tools at their disposal as Direxion rolls out four single-stock leveraged and inverse exchange-traded funds.
Eli Lilly, Palo Alto Networks Traders Take Note: Direxion's New Leveraged ETFs Are Here
Active traders have new, highly powered tools at their disposal as Direxion rolls out four single-stock leveraged and inverse exchange-traded funds.
2 No-Brainer Growth Stocks to Buy and Hold Forever
Don't let market volatility convince you otherwise: Investing in stocks remains one of the best ways to accumulate capital over long periods. It can be hard to remember that when equities are falling, and the market faces significant uncertainty due to macroeconomic factors -- precisely what we have experienced in 2025.
Eli Lilly (LLY) Stock Sinks As Market Gains: Here's Why
Eli Lilly (LLY) closed at $852.35 in the latest trading session, marking a -1.45% move from the prior day.
Healthy Returns: Novo Nordisk scoops up Chinese obesity drug to compete with Eli Lilly
Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors' perception of the health care system is improving.
Eli Lilly Shares Rise Over 2% After Key Signal
LLY CLIMBS OVER 17 POINTS AT ITS HIGH
Eli Lilly will soon release key data on its weight loss pill. Here's why it could be a game-changer
Eli Lilly plans to release initial results from several late-stage clinical trials on its experimental once-daily obesity pill, orforglipron, this year. The trial results are among the pharmaceutical industry's most critical of the year, as they will bring Eli Lilly's pill one step closer to becoming a new, needle-free alternative for weight loss and diabetes.
